T1	Participants 57 142	patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT.
T2	Participants 309 354	patients with poor left-ventricular function.
T3	Participants 1295 1364	1486 patients (743 in the amiodarone group, 743 in the placebo group)
